Genocea Biosciences, Inc. (GNCAQ)

Market Cap	59.00
Revenue (ttm)	1.91M
Net Income (ttm)	-37.19M
Shares Out	58.78M
EPS (ttm)	-0.53
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	15
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	31.84
RSI	48.08
Earnings Date	n/a

About Genocea Biosciences

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 74
• Stock Exchange: OTCMKTS
• Ticker Symbol: GNCAQ

Financial Performance

In 2021, Genocea Biosciences's revenue was $1.64 million, an increase of 20.75% compared to the previous year's $1.36 million. Losses were -$33.20 million, -24.06% less than in 2020.